Health
News Scan for Apr 19, 2021 – CIDRAP
CARB-X to fund development of bacteriophage-based drug
CARB-X announced today that it is awarding Phico Therapeutics of Cambridge, United Kingdom, up to $5.3 million to develop an intravenous bacteriophage drug to treat ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
The award will support development of Phico’s SASPject PT 3.9 project, which combines engineered bacteriophages with antibacterial small acid-soluble spore proteins (SASPs) to target and inactivate P aeruginosa bacteria….
-
General21 hours agoAntoinette Lattouf’s lawyers push for $350k penalty over ABC’s contraventions of Fair Work Act
-
Noosa News21 hours agoJudge draws on brother’s care – Proctor
-
Business21 hours agoAustralia’s highest earners are betting big on these ASX ETFs
-
General21 hours agoDeputy PM Richard Marles to address Israel lobby summit on Gold Coast